From The Editors September 2021

TOP - September 2021 Vol 14, No 5 - From the Editors
Patrick J. Medina, PharmD, BCOP
Medical Science Liaison
Medical Affairs, GlaxoSmithKline
Collegeville, PA
Adjunct Professor of Pharmacy
University of Oklahoma College of Pharmacy

The September issue of The Oncology Pharmacist (TOP) features important information for today’s oncology pharmacist, including highlights from presentations made during the American Society of Clinical Oncology (ASCO) 2021 virtual meeting and other key oncology conferences. Topics include recent advances in the treatment of several types of malignancies and ongoing efforts by stakeholders to address social and healthcare policy issues affecting the clinical outcomes of patients with cancer.

In an important presentation at ASCO 2021, Ferdinandos Skoulidis, MD, PhD, MRCP, discussed encouraging results from the CodeBreaK 100 clinical trial, which evaluated sotorasib in previously treated patients with non−small-cell lung cancer (see here).

“After nearly 4 decades of research, we now have an effective and well tolerated oral therapy against mutant KRAS—the most common driver oncogene in lung cancer,” he said.

In a separate session at ASCO 2021, Giuseppe Curigliano, MD, PhD, discussed updated results from the HER2CLIMB trial, which showed a survival benefit with the addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (see here).

“These data further support that treatment with the tucatinib regimen helps patients live longer compared with trastuzumab and capecitabine alone,” he stated.

During the 2021 Hematology/Oncology Pharmacy Association conference, experts identified disparities in cancer care that are associated with higher mortality rates and poorer clinical outcomes and discussed strategies for addressing and eliminating these disparities (see here).

“Instead of race, I propose that we push ourselves to ask, what is the difference [in cancer outcomes] stemming from?” said Benyam Muluneh, PharmD, BCOP, CPP. “Is it stemming from truly genetic differences, or is it stemming from racism?”

Additional topics in this issue of TOP include promising results from a trial evaluating tebentafusp in patients with metastatic uveal melanoma (see here), an in-depth review of infigratinib, which was recently approved by the FDA for the treatment of advanced or metastatic cholangiocarcinoma (see here), and the detrimental effects of the COVID-19 pandemic on the management of patients with cancer, including the implications for patients with lung cancer (see here).

As always, we hope you will enjoy this issue of TOP, and we invite you to visit www.TheOncologyPharmacist.com to share your feedback about this issue with us or send comments to info@TheOncologyPharmacist.com.

Related Items
From The Editors: November 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in From the Editors
From The Editors: October 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in From the Editors
From The Editors July 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in From the Editors
From The Editors May 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in From the Editors
From The Editors March 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - March 2021 Vol 14, No 2 published on March 11, 2021 in From the Editors
From The Editors January 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in From the Editors
From The Editors November 2020
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in From the Editors
From The Editors TOP Sept 2020
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in From the Editors
From The Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in From the Editors
From The Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in From the Editors
Last modified: September 8, 2021